The Prefrontal Lobotomy — a Nobel, 40,000 Wrecked Brains, Then a Pill Killed It

In November 1935 at Lisbon’s Santa Marta Hospital, Portuguese neurologist António Egas Moniz drilled into the skulls of his first twenty psychiatric patients, severing the white-matter tracts of the frontal lobes, and reported — on the basis of a few weeks of observation and no controls — that he had cured or improved most of them; the gap between that claim and the documented reality is the entire case. The reality was a procedure that, in its American form, lobotomized roughly 40,000 to 50,000 people, blunted or destroyed the personalities of a large fraction of them, killed on the order of one in twenty, and was performed most heavily on women, the institutionalized, children, and the powerless who could not consent. It was not validated against a sham, not measured against an inert comparator, not followed over the years it would have taken to see what it did; it was launched on the authority of a respected clinician working fast in a field that had nothing else to offer overcrowded asylums.

The operation did not fail quietly in a backwater. It was crowned. Moniz received the 1949 Nobel Prize in Physiology or Medicine “for his discovery of the therapeutic value of leucotomy in certain psychoses,” the only Nobel ever awarded for a surgical destruction of healthy brain tissue. That prize functioned as a regulatory and reputational green light: it converted an undertested operation into a respectable standard of care and supercharged its American evangelist, neurologist Walter Jackson Freeman II, who by the late 1960s had performed or supervised more than 3,500 lobotomies — a death toll among his own patients estimated at roughly 490.

Freeman’s signature innovation was to remove the operating room entirely. His “transorbital” or “ice-pick” lobotomy, first performed on a living patient on January 17, 1946, drove a leucotome through the thin bone of the eye socket and swept it across the frontal lobes, often in under ten minutes, frequently with no surgeon present and no general anaesthetic — he stunned patients with electroshock instead. He performed it on minors, on patients with headaches and depression, and on Rosemary Kennedy in 1941, who was left permanently incapacitated. The surrogate endpoint — a calmer, more “manageable” ward patient — was achieved. The actual endpoint — a recovered human being — usually was not.

The reckoning came not from a tribunal but from a molecule. Chlorpromazine, synthesized in 1950 and shown to control psychosis by 1952, offered the same institutional benefit — quieter, more tractable patients — without drilling through the skull. Within roughly a decade the lobotomy collapsed from a Nobel-honored frontier therapy to a byword for medical hubris. It was never recalled, never banned by a single statute; it was simply abandoned, made obsolete by a pill, and is now the textbook case of how prestige, a flattering surrogate measure, and an absence of controlled evidence can scale a mutilating procedure to tens of thousands before anyone is required to prove it works.